355 related articles for article (PubMed ID: 22252965)
1. Genomic and mutational profiling of ductal carcinomas in situ and matched adjacent invasive breast cancers reveals intra-tumour genetic heterogeneity and clonal selection.
Hernandez L; Wilkerson PM; Lambros MB; Campion-Flora A; Rodrigues DN; Gauthier A; Cabral C; Pawar V; Mackay A; A'Hern R; Marchiò C; Palacios J; Natrajan R; Weigelt B; Reis-Filho JS
J Pathol; 2012 May; 227(1):42-52. PubMed ID: 22252965
[TBL] [Abstract][Full Text] [Related]
2. Whole-Exome Sequencing Analysis of the Progression from Non-Low-Grade Ductal Carcinoma
Pareja F; Brown DN; Lee JY; Da Cruz Paula A; Selenica P; Bi R; Geyer FC; Gazzo A; da Silva EM; Vahdatinia M; Stylianou AA; Ferrando L; Wen HY; Hicks JB; Weigelt B; Reis-Filho JS
Clin Cancer Res; 2020 Jul; 26(14):3682-3693. PubMed ID: 32220886
[TBL] [Abstract][Full Text] [Related]
3. Single-cell genetic analysis of ductal carcinoma in situ and invasive breast cancer reveals enormous tumor heterogeneity yet conserved genomic imbalances and gain of MYC during progression.
Heselmeyer-Haddad K; Berroa Garcia LY; Bradley A; Ortiz-Melendez C; Lee WJ; Christensen R; Prindiville SA; Calzone KA; Soballe PW; Hu Y; Chowdhury SA; Schwartz R; Schäffer AA; Ried T
Am J Pathol; 2012 Nov; 181(5):1807-22. PubMed ID: 23062488
[TBL] [Abstract][Full Text] [Related]
4. HER2 status in pure ductal carcinoma in situ and in the intraductal and invasive components of invasive ductal carcinoma determined by fluorescence in situ hybridization and immunohistochemistry.
Park K; Han S; Kim HJ; Kim J; Shin E
Histopathology; 2006 May; 48(6):702-7. PubMed ID: 16681686
[TBL] [Abstract][Full Text] [Related]
5. Extensive ductal carcinoma In situ with small foci of invasive ductal carcinoma: evidence of genetic resemblance by CGH.
Aubele M; Mattis A; Zitzelsberger H; Walch A; Kremer M; Welzl G; Höfler H; Werner M
Int J Cancer; 2000 Jan; 85(1):82-6. PubMed ID: 10585588
[TBL] [Abstract][Full Text] [Related]
6. Comparable cancer-relevant mutation profiles in synchronous ductal carcinoma in situ and invasive breast cancer.
Bergholtz H; Kumar S; Wärnberg F; Lüders T; Kristensen V; Sørlie T
Cancer Rep (Hoboken); 2020 Jun; 3(3):e1248. PubMed ID: 32671987
[TBL] [Abstract][Full Text] [Related]
7. Gene expression profiling of tumour epithelial and stromal compartments during breast cancer progression.
Vargas AC; McCart Reed AE; Waddell N; Lane A; Reid LE; Smart CE; Cocciardi S; da Silva L; Song S; Chenevix-Trench G; Simpson PT; Lakhani SR
Breast Cancer Res Treat; 2012 Aug; 135(1):153-65. PubMed ID: 22718308
[TBL] [Abstract][Full Text] [Related]
8. PI3K pathway activation in high-grade ductal carcinoma in situ--implications for progression to invasive breast carcinoma.
Sakr RA; Weigelt B; Chandarlapaty S; Andrade VP; Guerini-Rocco E; Giri D; Ng CK; Cowell CF; Rosen N; Reis-Filho JS; King TA
Clin Cancer Res; 2014 May; 20(9):2326-37. PubMed ID: 24634376
[TBL] [Abstract][Full Text] [Related]
9. PIK3CA mutations in ductal carcinoma in situ and adjacent invasive breast cancer.
Agahozo MC; Sieuwerts AM; Doebar SC; Verhoef EI; Beaufort CM; Ruigrok-Ritstier K; de Weerd V; Sleddens HFBM; Dinjens WNM; Martens JWM; van Deurzen CHM
Endocr Relat Cancer; 2019 May; 26(5):471-482. PubMed ID: 30844755
[TBL] [Abstract][Full Text] [Related]
10. Immunophenotypic and genomic characterization of papillary carcinomas of the breast.
Duprez R; Wilkerson PM; Lacroix-Triki M; Lambros MB; MacKay A; A'Hern R; Gauthier A; Pawar V; Colombo PE; Daley F; Natrajan R; Ward E; MacGrogan G; Arbion F; Michenet P; Weigelt B; Vincent-Salomon A; Reis-Filho JS
J Pathol; 2012 Feb; 226(3):427-441. PubMed ID: 22025283
[TBL] [Abstract][Full Text] [Related]
11. Comparison of HER2 amplification status among breast cancer subgroups offers new insights in pathways of breast cancer progression.
Lambein K; Van Bockstal M; Vandemaele L; Van den Broecke R; Cocquyt V; Geenen S; Denys H; Libbrecht L
Virchows Arch; 2017 Nov; 471(5):575-587. PubMed ID: 28567637
[TBL] [Abstract][Full Text] [Related]
12. Molecular diversity in ductal carcinoma in situ (DCIS) and early invasive breast cancer.
Muggerud AA; Hallett M; Johnsen H; Kleivi K; Zhou W; Tahmasebpoor S; Amini RM; Botling J; Børresen-Dale AL; Sørlie T; Wärnberg F
Mol Oncol; 2010 Aug; 4(4):357-68. PubMed ID: 20663721
[TBL] [Abstract][Full Text] [Related]
13. Progression of ductal carcinoma in situ to invasive breast cancer: comparative genomic sequencing.
Doebar SC; Krol NM; van Marion R; Brouwer RWW; van Ijcken WFJ; Martens JM; Dinjens WNM; van Deurzen CHM
Virchows Arch; 2019 Feb; 474(2):247-251. PubMed ID: 30284611
[TBL] [Abstract][Full Text] [Related]
14. Genomic differences between pure ductal carcinoma in situ and synchronous ductal carcinoma in situ with invasive breast cancer.
Kim SY; Jung SH; Kim MS; Baek IP; Lee SH; Kim TM; Chung YJ; Lee SH
Oncotarget; 2015 Apr; 6(10):7597-607. PubMed ID: 25831047
[TBL] [Abstract][Full Text] [Related]
15. Identification of copy number alterations associated with the progression of DCIS to invasive ductal carcinoma.
Johnson CE; Gorringe KL; Thompson ER; Opeskin K; Boyle SE; Wang Y; Hill P; Mann GB; Campbell IG
Breast Cancer Res Treat; 2012 Jun; 133(3):889-98. PubMed ID: 22052326
[TBL] [Abstract][Full Text] [Related]
16. Genomic differences between pure ductal carcinoma in situ of the breast and that associated with invasive disease: a calibrated aCGH study.
Iakovlev VV; Arneson NC; Wong V; Wang C; Leung S; Iakovleva G; Warren K; Pintilie M; Done SJ
Clin Cancer Res; 2008 Jul; 14(14):4446-54. PubMed ID: 18628458
[TBL] [Abstract][Full Text] [Related]
17. Multi-omic profiling of simultaneous ductal carcinoma in situ and invasive breast cancer.
Kaplan HG; Dowdell AK; Berry AB; Shimol RB; Robinson FL; Carney CA; Piening BD
Breast Cancer Res Treat; 2024 Jun; 205(3):451-464. PubMed ID: 38523186
[TBL] [Abstract][Full Text] [Related]
18. Identifying a highly-aggressive DCIS subgroup by studying intra-individual DCIS heterogeneity among invasive breast cancer patients.
Pape-Zambito D; Jiang Z; Wu H; Devarajan K; Slater CM; Cai KQ; Patchefsky A; Daly MB; Chen X
PLoS One; 2014; 9(6):e100488. PubMed ID: 24978026
[TBL] [Abstract][Full Text] [Related]
19. Genetic changes in intraductal breast cancer detected by comparative genomic hybridization.
Kuukasjärvi T; Tanner M; Pennanen S; Karhu R; Kallioniemi OP; Isola J
Am J Pathol; 1997 Apr; 150(4):1465-71. PubMed ID: 9095001
[TBL] [Abstract][Full Text] [Related]
20. Three-dimensional modelling identifies novel genetic dependencies associated with breast cancer progression in the isogenic MCF10 model.
Maguire SL; Peck B; Wai PT; Campbell J; Barker H; Gulati A; Daley F; Vyse S; Huang P; Lord CJ; Farnie G; Brennan K; Natrajan R
J Pathol; 2016 Nov; 240(3):315-328. PubMed ID: 27512948
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
